missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ PAK6 Polyclonal Antibody

Beschreibung
Reconstitute at 0.2 mg/mL in sterile PBS.
PAK6 is a serine/threonine kinase expressed in the testis and prostate. It associates with both the estrogen and androgen receptors. The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6. These proteins are not activated by Cdc42/Rac binding. Later experiments have shown it to be activated by MAP kinase kinase 6 and p38 MAP kinase, suggesting that PAK6 may play a role in the cellular response to stress-related signals.
Spezifikation
Spezifikation
| Antigen | PAK6 |
| Anwendungen | Western Blot |
| Klassifikation | Polyclonal |
| Konzentration | 0.2 mg/mL |
| Konjugat | Unconjugated |
| Zusammensetzung | PBS with trehalose and no preservative |
| Gen | Pak6 |
| Gen-Zugriffsnummer | Q3ULB5, Q9NQU5 |
| Gen-Alias | 4732456M09; p21 (CDKN1A)-activated kinase 6; p21 (RAC1) activated kinase 6; p21 protein (Cdc42/Rac)-activated kinase 6; p21(CDKN1A)-activated kinase 6; p21-activated kinase 6; PAK5; PAK-5; PAK6; PAK-6; Serine/threonine-protein kinase PAK 6 |
| Gensymbole | Pak6 |
| Mehr anzeigen |
Name des Produkts
Indem Sie auf Absenden klicken, erklären Sie sich damit einverstanden, dass Fisher Scientific sich mit Ihnen in Verbindung setzen kann, um Ihr Feedback in diesem Formular zu bearbeiten. Wir werden Ihre Informationen nicht für andere Zwecke weitergeben. Alle bereitgestellten Kontaktinformationen werden in Übereinstimmung mit unserer Datenschutzrichtlinie aufbewahrt. Datenschutzrichtlinie.
Haben Sie Verbesserungsvorschläge?